CANF Can-Fite Biopharma Ltd Sponsore

1.78
+0.03  (2%)
Previous Close 1.75
Open 1.79
Price To book 5.95
Market Cap 29.11M
Shares 16,354,000
Volume 24,868
Short Ratio 2.76
Av. Daily Volume 71,976

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 failed to meet endpoint - July 2016
CF101
Glaucoma
Phase 2 enrollment to be completed 2Q 2017.
Namodenoson (CF102)
Cancer - advanced liver cancer second line
Phase 3 enrollment to commence 2Q 2017.
CF101
Rheumatoid arthritis
Phase 2/3 trial did not meet primary endpoint late March 2015. Additional Phase 3 planned, with trial protocol to be submitted 4Q 2017.
CF101
Psoriasis
Phase 2 enrollment to commence with a few weeks - as of May 3, 2017.
CF102
Non-alcoholic steatohepatitis (NASH)

Latest News

  1. Can-Fite Files Clinical Trial Application in Canada for Piclidenoson Ahead of Upcoming Acrobat Rheumatoid Arthritis Phase III Study
  2. Can-Fite's Liver Protective Drug Namodenoson Enters Phase II Trial for Treatment of NAFLD/NASH
  3. Can-Fite's Phase III ACRobat Trial in Rheumatoid Arthritis Approved by Institutional Review Board
  4. Can-Fite Reports 2016 Financial Results & Provides Clinical Update
  5. New Preclinical Data Show Can-Fite's Namodenoson (CF102) Prevents Progression of Liver Fibrosis
  6. CANF: Ready to Start Two Phase III Trials in 2017
  7. Can-Fite Gears Up for ACRobat, its Phase III Trial of Piclidenoson in Rheumatoid Arthritis
  8. Can-Fite BioPharma Announces $5 Million Registered Direct Offering
  9. Can-Fite Receives IRB Approval to Commence Patient Enrollment in Phase II NAFLD/NASH Trial in Q1 2017
  10. Can-Fite Receives $500,000 Payment as Part of $3 Million Distribution Deal for Liver Cancer Drug Namodenoson (CF102) in South Korea
  11. New Preclinical Data Show Can-Fite's Namodenoson (CF102) Inhibits Liver Fibrosis -- Supports Potential Efficacy in Treatment of NASH
  12. Can-Fite Reports Financial Results for Nine Months Ended September 30, 2016 & Provides Clinical Update
  13. American Medical Association's USAN & World Health Organization's INN Approve "Namodenoson" as Generic Name for Can-Fite's Liver Drug CF102
  14. Can-Fite to Participate in BIO-Europe Partnering Conference on November 7-9, 2016 in Cologne, Germany
  15. Can-Fite Advances Towards a Pivotal Phase III Clinical Trial in Psoriasis with Piclidenoson (CF101) Following Reaching Agreement with EMA
  16. Can-Fite Submits Protocol for NAFLD/NASH CF102 Drug (CANF)
  17. Can-Fite Submits Protocol for Phase II Trial of CF102 in the Treatment of NAFLD/NASH
  18. Positive Data on Liver Cancer Drug (CANF)
  19. Can-Fite Reports New Data on CF102's Liver Protective & Regenerative Properties Published in Scientific Journal
  20. Can-Fite Secures Patent for Psoriasis Treatment